Merit Medical Systems is a global medical device company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and supplies for various clinical applications
The company focuses primarily on products used in the fields of interventional cardiology, radiology, and critical care, offering innovative solutions that enhance patient care and treatment outcomes. Merit's portfolio includes advanced catheter systems, diagnostic and therapeutic products, as well as specialty surgical devices. With a commitment to quality and innovation, Merit Medical aims to meet the evolving needs of healthcare professionals and improve the overall healthcare experience for patients.
Medical device company Merit Medical Systems (NASDAQMMSI) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.4% year on year to $355.2 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.93 per share was 12.2% above analysts’ consensus estimates.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSEAORT) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including ICU Medical (NASDAQICUI) and its peers.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSEPEN) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems (NASDAQMMSI) and its peers.
Merit Medical Systems plans to acquire Cook Medical's lead management portfolio for $210 million, aiming to boost its electrophysiology and cardiac rhythm management business. The deal is expected to close in Q4 2024 and contribute to Merit's global cardiac intervention market revenue.
